Adverse events following immunization during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo: Findings from active safety surveillance
PLOS One · 10.07.2026 · 21 (7) · e0309628
DOI: 10.1371/journal.pone.0309628 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 10.07.2026. Verfasst von Kizito Kayumba und 17 weiteren Autor:innen. Beteiligte Einrichtung: Africa Centres for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia. Hauptthemen laut MEDLINE: Mass Vaccination, COVID-19 Vaccines, COVID-19. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mastercard Foundation.
Themen: Patientensicherheit
Abstract (Originalsprache)
Introduction
Post-marketing safety surveillance is essential for ensuring vaccine safety and maintaining public trust, particularly in African settings where evidence on the safety of COVID–19 vaccines remains limited. This study aimed to determine the overall incidence and types of AEFIs, as well as the factors associated with their occurrence, during COVI-19 mass vaccination campaigns in Democratic Republic of Congo.
Methods
From December 1–29, 2023, a prospective safety surveillance study was conducted in Kinshasa Province. Participants were surveyed through phone calls from day 1–28 following COVID-19 vaccine administration. AEFI incidence rates were calculated by type of vaccine, sex, number of dose and age group. Factors associated with AEFIs were identified using multivariable logistic regression models, expressed by adjusted odds ratio and its 95% confidence interval.
Results
The study included 4766 participants. Their median [IQR] age was 36 [27−48] years and 2503 (53%) were males, 94.63% received the J&J vaccine while 256 (5.37%) received the BNT162b2 vaccine. Incidence of AEFIs was 23.75% (95%CI: 22.54%−24.99%). AEFIs mostly reported were fever (9.61%, 95%CI: 8.88%−10.48%), injection site pain (9.00%, 95%CI: 8.20%−9.85%), headache (4.11%, 95%CI: 3.57%−4.72%), stiffness (1.51%, 95%CI: 1.18%−1.89%) and myalgia (1.15%, 95%CI: 0.87%−1.49%). The incidence of AEFIs was higher for the BNT162b2 vaccine at 34.48% (95% CI: 28.57%−40.54%) vs. 23.15% (95% CI: 21.92%−24.41%) for the J&J vaccine. Compared to participants aged 18−59 years, those under 18 years old were associated with decreased odds of reporting any AEFI (aOR= 0.26, 95%CI: 0.13–0.88) and injection site pain (aOR=0.18, 95%CI: 0.05–0.75). Those aged 60 years and older were associated with decreased odds of reporting any AEFI (aOR= 0.78, 95%CI: 0.62–0.99) and fever (aOR=0. 63, 95%CI: 0.43–0.92).
Conclusions
Approximately one-quarter of participants reported AEFI. The observed association with vaccine type and age underscores the need for systematic vaccine safety monitoring in the population. This is critical for guiding future vaccination strategies tailored to individuals who may be more susceptible to AEFIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Africa Centres for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia.
- Ministry of Health, Kinshasa, Democratic Republic of Congo.
ORCID-Profile: Kizito Kayumba, Nicaise Ndembi
Förderung
- Mastercard Foundation
Zitieren
APA
Kayumba, K., Duga, A., Papa Fallah, M., Tshidibi, C., Lubaki, N., Coulibaly, B., Djoudalbaye, B., Nora Sylvana, E., Sembuche, S. L., Tilahun, T., Jibril, M., Kilowe, C., Kuba, A., Mafwila Lusala, A., Dereje, N., Ndembi, N., Raji, T., & Ngongo, N. (2026). Adverse events following immunization during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo: Findings from active safety surveillance. PLOS One, 21(7), e0309628. https://doi.org/10.1371/journal.pone.0309628
Vancouver
Kayumba K, Duga A, Papa Fallah M, Tshidibi C, Lubaki N, Coulibaly B, et al. Adverse events following immunization during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo: Findings from active safety surveillance. PLOS One. 2026;21(7):e0309628. doi:10.1371/journal.pone.0309628
BibTeX
@article{Kayumba2026,
author = {Kayumba, Kizito and Duga, Alemayehu and Papa Fallah, Mosoka and Tshidibi, Claire and Lubaki, Nicky and Coulibaly, Barnabas and Djoudalbaye, Benjamin and Nora Sylvana, Efire and Sembuche, Senga Lucy and Tilahun, Tedi and Jibril, Murtala and Kilowe, Carlos and Kuba, Aminu and Mafwila Lusala, Antoine and Dereje, Nebiyu and Ndembi, Nicaise and Raji, Tajudeen and Ngongo, Ngashi},
title = {Adverse events following immunization during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo: Findings from active safety surveillance},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0309628},
doi = {10.1371/journal.pone.0309628}
}
EUVIMED